ESMO 2025 – Sanofi takes aim at Lutathera
But Perspective sinks again.
ESMO 2025 – Novartis looks for Pluvicto prostate Addition
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
Grit enters the in vivo Car-T race
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
ESMO 2025 preview – Sanofi’s lead shot gets a boost
The group toplines a phase 2 win with Alphamedix.
Y-Mabs falls to Serb
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
Telix sees more backing for LAT1
TLX101 follows Ipax-1 with an apparent success in an academic trial.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
